Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Market Cap	292.58B
Revenue (ttm)	156.01B
Net Income (ttm)	21.76B
Shares Out	72.96M
EPS (ttm)	295.15
PE Ratio	13.59
Forward PE	12.44
Dividend	90.00 (2.25%)
Ex-Dividend Date	Aug 28, 2025

Volume	223,400
Average Volume	153,735
Open	3,992.00
Previous Close	4,010.00
Day's Range	3,964.00 - 4,021.00
52-Week Range	3,708.00 - 4,735.00
Beta	0.38
RSI	38.41
Earnings Date	Jul 10, 2025

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,799
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.